chronic limb-threatening ischemia - search results
If you're not happy with the results, please do another search
Incorporation of Shockwave E8 Peripheral IVL into the treatment of patients with chronic limb-threatening...
This advertorial is sponsored by Shockwave Medical.
Anand Prasad, MD, an 18-year veteran of vascular and endovascular medicine with a particular interest in peripheral arterial...
Urban residents have smaller risk of mortality from chronic limb-threatening ischemia
A new study using data from millions of patients hospitalized across the U.S. has determined whether population density and associated urban versus suburban versus...
Deep vein arterialization: Much remains to be learned but use poised to expand in...
These remain early days for transcatheter arterialization of the deep veins (TADV) in the setting of patients with severe chronic limb-threatening ischemia (CLTI), says...
Claudication: Medicare-linked data outline higher rates of progression to CLTI after revascularization among Black...
Black women with claudication had the highest rate of progression to chronic limb-threatening ischemia (CLTI) after lower extremity revascularization at 180 days, new data...
Missing a step? Searching for meaning in claudication research
A team of leading vascular surgeons in the care of patients with PAD weigh up evidence for the treatment of claudication, calling for research...
Meta-analysis: Drug-coated devices show comparable aggregate outcomes to non-drug-coated devices in CLTI
Drug-coated balloon (DCB) angioplasty appears to offer similar benefits as plain old balloon angioplasty (POBA), with or without stenting, for patients with chronic limb-threatening...
‘We need to look at the totality of evidence’: VIVA panelists examine SWEDEPAD findings
A focused session at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA) homed in on the latest findings from the...
Cracking CLTI: How Shockwave Javelin intravascular lithotripsy is opening up new frontiers in heavily...
This advertorial is sponsored by Shockwave Medical.
Three vascular surgeons discuss how and when they deploy the transformative Shockwave Javelin first-of-its-kind Forward Intravascular Lithotripsy (IVL)...
PROMISE III: Six-month data ‘reinforce’ case for TADV in no-option CLTI patients
Six-month outcomes among no-option chronic limb-threatening ischemia (CLTI) patients treated using transcatheter arterialization of the deep veins with the LimFlow system (Stryker/Inari Medical) in...
Vein mapping rates show no sign of change two years after BEST-CLI, new study...
Vein mapping for lower extremity bypass in patients with chronic limb-threatening ischemia (CLTI) remains unchanged two years after the BEST-CLI, "revealing the difficulty in...
TADV without venous branch coiling still yields strong limb salvage rates among ‘no-option’ CLTI...
Transcatheter arterialization of deep veins (TADV) done without the coiling of venous outflow branches achieved sufficient distal perfusion after three months among “no-option” chronic...
The intersection of palliative care and vascular surgery
As vascular surgeons, we strive to practice comprehensive vascular surgery care. This entails the medical and surgical management of patients with a wide range...
Designated multispecialty CLTI teams may help in amputation fight
Teams formally defined as specializing in chronic limb-threatening ischemia (CLTI) were associated with a decreased risk of major amputation among a subset of BEST-CLI...
Shifting demographics, improved visibility and strides made on Medicare reimbursements
This is the latest monthly update on a few of the critical issues facing the SVS.
Changing SVS leadership demographics
Over the last several years,...
Enduring PROMISE: Real-world outcomes study suggests results continue to flow from transcatheter arterialization of...
First retrospective analysis shows comparable outcomes data to those found in PROMISE II pivotal trial, authors report.
The first post-approval multicenter analysis of so-called “no-option”...
Advances in endovascular therapy help drive innovative CPVI training course
The SVS Complex Peripheral Vascular Interventions (CPVI) Skills Course has become a fixture on the vascular surgery calendar over the past couple of years....
First patient enrolled in AngioDynamics’ AMBITION BTK trial for CLTI
AngioDynamics today announced enrollment of the first patient in AMBITION BTK, a randomized study of the Auryon atherectomy system in patients with below-the-knee chronic...
Complex PAD skills course registration is open
Registration is now open for the Society for Vascular Surgery (SVS) Complex Peripheral Vascular Interventions (CPVI) Skills Course, taking place from Sept. 20–21 in...
Novel MRI technique for CLTI poised to address ‘medieval problem in modern medicine’
“We want to change global standards. What we’re doing isn’t working. Patients are getting hurt and devices are failing—we want to be able to...
StentIt launches first-in-human trial of bioresorbable stent to treat below-the-knee CLTI
StentIt has announced the successful implantation of its Resorbable Fibrillated Scaffold (RFS). As part of the VITAL-IT 1 study, patients with chronic limb-threatening ischemia...
International Chapter highlights pressing need to document PAD and CLTI prevalence in South Asia
There is an urgent need for epidemiological studies to map out the prevalence of chronic limb-threatening ischemia (CLTI)—and peripheral arterial disease (PAD) in general—in...
Transcatheter arterialization of the deep veins: Comparative analysis probes whether emerging modality is worth...
“We're living in a new world order” when it comes to “no-option” chronic limb-threatening ischemia (CLTI) patients, says Anahita Dua, MD. In recent years,...
Long-term VQI-VISION analysis sheds light on PVI versus bypass in aortoiliac occlusive disease
Today's Plenary Session 4—Hosted in Great Hall A, First Floor from 10:45 a.m.–12 p.m.—will feature a presentation of five-year findings from the VQI-VISION database...
Cost-effectiveness outcomes defy expectations in latest BEST-CLI data drop
The open surgical approach will prove to be “slightly superior” to endovascular intervention in terms of cost per life year gained, while the latter...
The Survivalist’s Guide to Heart and Vascular Centers
Malachi Sheahan III, MD, produces notes on a quixotic quest to find meaning in one of medicine’s most meaningless endeavors.
Here’s how it happens. One...
New study validates BEST-CLI trial results, ‘suggesting generalizability’
A new propensity-matched analysis of more than 1,100 lower extremity revascularization procedures carried out in patients with chronic limb-threatening ischemia (CLTI)—which aimed to help...
Mentorship takes center stage at VRIC 2025
The Vascular Research Initiatives Conference (VRIC) will spotlight the crucial role of mentorship in advancing the fields of vascular surgery and research during its...
Corner Stitch: Becoming a community-engaged vascular surgeon
At the end of my intern year, I was tired. It had been a long year of rounding, placing orders, seeing consults and refining...
SVS leadership and membership integral to ‘far-reaching’ BEST-CLI trial
Support from the Society for Vascular Surgery (SVS) and, later, funding from the SVS Foundation were integral to the BEST-CLI trial, said one of...
2024 in review: Message from the SVS executive director
The Society for Vascular Surgery (SVS) takes a moment to recognize the dedication, achievements and progress made over the past year. In a letter...
Intermittent Topical Wound Oxygen: ‘It needs to no longer be seen as late-stage therapy’
This advertorial is sponsored by AOTI.
Two prominent vascular surgeons discuss a rising tide of evidence pointing toward benefits of adjunct use of cyclically pressurized...
Study demonstrates textbook outcomes occur less than a quarter of the time after CLTI...
Textbook outcomes remain “very rare” after revascularization for chronic limb-threatening ischemia (CLTI), with the main driver being an enduring inability to attain complete wound...
BEST-CLI trial spline model analysis breaks new ground in assessing the impact of CKD...
A new analysis of the BEST-CLI trial has produced the first evidence-based glomerular filtration rate (eGFR) value—30 mL/min/1.73 m2—as the cutoff below which patients...
SVS gets moving on PAD-related grant
All those steps logged during the SVS Foundation’s exercise challenge in September will help the Foundation—and researchers—take new steps to unlock new treatments for...
Novel sirolimus-eluting scaffold system demonstrates ‘potential to address Achilles’ heel’ of currently available endovascular...
Ongoing studies of the Efemoral vascular scaffold system (EVSS)—previously described as a potential new paradigm in the treatment of long occlusive lesions—show that the...
BEST-CLI: Trial results endure in analysis of patients who presented with diabetes
Diabetes affects approximately 70% of patients with chronic limb-threatening ischemia (CLTI) and is associated with more severe presentation, driven mostly by higher rates of...
Research suggests arm vein is the best alternative bypass conduit to GSV in patients...
A new analysis has found arm vein to be the most suitable alternative conduit to great saphenous vein (GSV) in chronic limb-threatening ischemia (CLTI)...
The top 10 most popular Vascular Specialist stories of October 2024
In October, the most read stories from Vascular Specialist included a new leadership announcement from the American College of Surgeons (ACS); study results examining a...
Endoscopic vein harvest under the microscope
Conflicting results open fresh debate around effect of vein harvesting technique on long-term patency of lower extremity bypass grafts.
Two separate analyses that looked at...
The Shockwave E8 experience: Featuring the new Shockwave peripheral IVL workhorse
This advertorial is sponsored by Shockwave Medical.
Paul J. Foley III, MD, a vascular surgeon and director of the non-invasive vascular lab at Doylestown Hospital...
Smoking: BEST-CLI trial points to protective effect against MALE in those undergoing open bypass...
An analysis of the BEST-CLI randomized controlled trial (RCT) found that smokers with chronic limb-threatening ischemia (CLTI) should be preferentially treated with open bypass...
The top 10 most popular Vascular Specialist stories of September 2024
In September, the most read stories from Vascular Specialist included a change in leadership for the Midwestern Vascular Surgical Society; study results examining new treatment...
The CLTI conundrum: My spirited journey through the CLTI saga
Welcome to the CLTI Chronicles, a saga of mystery, medicine and misadventures in limb salvage unfolding weekly in my office, where the drama of...
VQI analysis of CLTI practice following BEST-CLI finds no pick up in bypass rate
A Vascular Quality Initiative (VQI) analysis of evolving practice in the wake of the BEST-CLI trial demonstrated no increase in the rate of surgical...
Pilot study looks at undiagnosed vascular disease in homeless
A pilot study in Canadian capital Ottawa aimed at uncovering the extent of undiagnosed vascular disease among the city’s homeless population detected a subset...
‘Select CLTI patients may be safely treated in the office-based lab’
Results from a single-center analysis show the outpatient setting met SVS objective performance goals.
A retrospective study of endovascular interventions performed for chronic limb-threatening ischemia...
Shockwave Medical expands US peripheral IVL portfolio with enhanced catheter
Shockwave Medical, part of Johnson & Johnson MedTech, has announced the full U.S. launch of its Shockwave E8 peripheral intravascular lithotripsy (IVL) catheter, following...
The top 10 most popular Vascular Specialist stories of August 2024
In August, the most read stories from Vascular Specialist included a research letter addressing ‘alarmingly high’ mortality rates in chronic limb-threatening ischemia (CLTI) patients; a new...
SCOREPAD seeks to address ‘alarmingly high’ mortality in CLTI patients with underlying coronary disease
A new research letter underscores the need to improve long-term survival following lower extremity revascularization for chronic limb-threatening ischemia (CLTI), setting out a randomized...
SVS Annual Business Meeting showcases 2024 Foundation award recipients
The Society for Vascular Surgery (SVS) convened its Annual Business Meeting at the Vascular Annual Meeting (VAM) on June 22 in Chicago.
A highlight...
Endovascular CFA treatment associated with increased rate of long-term CFA-specific reintervention, study finds
A recent study suggests that endovascular treatment of the common femoral artery (CFA) is associated with an increased rate of long-term CFA-specific reintervention, regardless...
Endovascular CFA treatment associated with increased rate of long-term CFA-specific reintervention, study finds
A recent study suggests that endovascular treatment of the common femoral artery (CFA) is associated with an increased rate of long-term CFA-specific reintervention, regardless...
Toe and flow session aims to break down barriers to multidisciplinary limb salvage teams
If you had cancer you would go to a cancer center where you would get a multidisciplinary approach,” SVS President Joseph Mills, MD, tells...
Dedicated session offers insight on ebbs and flows of SVS, ESVS guidelines
An education session set to take place in the afternoon of Wednesday, June 19 (3:15–4:45 p.m. in the West Building, Level 1), will examine...
VAM 2024: Enhancing clinical practice and patient interaction in CLTI
A key event on informed decision-making in chronic limb-threatening ischemia (CLTI) promises to be a highlight of the 2024 Vascular Annual Meeting (June 19–22). Funded...
BEST-CLI and the BASIL trials: Motion sees audience move in favor of endovascular therapy...
During the 2024 Charing Cross (CX) International Symposium in London, England (April 23–25), a Great Debate that pitted four global peripheral arterial disease (PAD)...
PAD guideline update from ACC, AHA and others centers multispecialty care
New multisociety clinical practice guidelines for the management of lower extremity peripheral arterial disease (PAD) have been published online in the Journal of the...
CMS considers new approaches to quality payment program with MVPs
The Centers for Medicare & Medicaid Services (CMS) are exploring strategies to enhance the Quality Payment Program (QPP), underscoring an effort to boost healthcare...
Vascular surgery Entrustable Professional Activities available to view
The American Board of Surgery (ABS) has unveiled the 15 proposed core Entrustable Professional Activities (EPAs) that will be evaluated in vascular surgery residents.
They...
Abbott’s Esprit BTK scaffold system given US FDA approval for CLTI treatment
Abbott has announced that the US Food and Drug Administration (FDA) has approved the Esprit BTK everolimus-eluting resorbable scaffold system (Esprit BTK system), a...
FDA Breakthrough Device designation granted for DynamX BTK for use in CLTI treatment below...
Elixir Medical has announced Breakthrough Device designation by the Food and Drug Administration (FDA) for its novel DynamX BTK System, an implant for use...
IVUS use in claudicants not associated with improved outcomes, claims data show
The use of intravascular ultrasound (IVUS) for the treatment of claudication doubled over a four-year period but there was “no clear relationship between IVUS...
Landmark BEST-CLI trial gains recognition as top cardiovascular advance in 2023
The American Heart Association (AHA) has named the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb ischemia) trial one of...
Make a ‘PLAN’ for CLTI by tuning into new webinar
An upcoming webinar is set to provide insights for healthcare professionals aiming to enhance their expertise in treating patients with chronic limb-threatening ischemia (CLTI)....
Breakthrough Device designation granted for Efemoral scaffold system designed to treat CLTI
Efemoral Medical has announced the granting of Food and Drug Administration (FDA) Breakthrough Device status for its novel Efemoral vascular scaffold system (EVSS) designed...
The top 10 most popular Vascular Specialist stories of January 2024
In January, the most read stories from Vascular Specialist include a U.S. Aortic Research Consortium analysis of F/BEVAR preoperative risk factors in AAAs/TAAAs; a...
SVS points to 2023 achievements, challenges in coming year
The Society for Vascular Surgery (SVS) reflects on a year marked by notable achievements on multiple fronts. In a communication to members in mid-December,...
BEST-CLI: A year down the road
A dedicated session at the 2023 VEITHsymposium (Nov. 14–18) in New York City aimed to unpack the ways in which clinical practice and attitudes...
SVS receives CMSS grant to advance diagnostic excellence
The Society for Vascular Surgery (SVS) has received a $100,000 grant from the Council of Medical Specialty Societies (CMSS) to promote diagnostic excellence across...
Changing course: The natural history of tibial claudication comes under scrutiny as interventions for...
In the end, reflected Michael S. Conte, MD, “it’s not the evidence.” The leading vascular surgeon and peripheral arterial disease (PAD) expert made the...
SVS executive director elected to executive council of Council of Medical Specialty Societies
The Society for Vascular Surgery (SVS) Executive Director Kenneth M. Slaw, PhD, has been elected to executive council of the Council of Medical Specialty...
The top 10 most popular Vascular Specialist stories of October 2023
Last month, the most popular stories from Vascular Specialist included The Centers for Medicare & Medicaid Services (CMS) confirmation of carotid artery stenting coverage expansion;...
CLTI: European cohort study provides ‘strong positive evidence’ for surgery over endovascular approach, supporting...
A recently published study has shown that lower limb bypass surgery offered a significantly higher probability of amputation-free survival and wound healing compared with...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Results of the LIFE-BTK randomized controlled trial have just been presented at TCT 2023 (Oct. 23–26) in San Francisco. The data show that, in...
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in complex CLTI cohort
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening...
The top 10 most popular Vascular Specialist stories of September 2023
Last month, the most read stories from Vascular Specialist included data releases from the recent Midwestern Vascular Surgical Society (MVSS) using direct revascularization of segmental...
When women are PIs: A story foretold on the vascular frontlines
“Multifactorial” issues persist in gender representation in vascular leadership and trial enrollment, leading women vascular surgeons tell Vascular Specialist.
"We would have fewer untoward side...
FDA approves LimFlow system for ‘no-option’ CLTI patients
The Food and Drug Administration (FDA) today announced approval of LimFlow therapy—a novel and minimally invasive procedure designed to bypass blockages in arteries of...
VQI Fellows in Training program marks one year
The Vascular Quality Initiative (VQI) Fellows in Training (FIT) program is a success, said leaders as they provided a one-year review.
FIT introduces residents and...
SVS responds to New York Times article on overuse of vascular interventions
In an official Society response, SVS President Joseph Mills, MD, tackles recent coverage in the mainstream media of inappropriateness in vascular care.
There have been...
Second edition of VSITE review text released
The second edition of a hit trainee-created textbook primarily aimed at those taking the Vascular Surgery In-Training Exam (VSITE) has hit the shelves.
The Vascular...
New analysis probes BEST-CLI trial against real-world setting data
A new analysis of chronic limb-threatening ischemia (CLTI) treatment outcomes was presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions...
Frailty status beats WIfI score as mortality predictor in all-comer CLTI study
A study presented during Plenary Session 3 at last week’s Vascular Annual Meeting (VAM), concluded that the Wound, Ischemia, and Foot Infection (WIfI) stage...
BEST-CLI investigators implore a move beyond endo vs. open ‘battle’ in the name of...
The principal investigators behind the BEST-CLI trial struck a conciliatory tone during the inaugural Frank J. Veith Distinguished Lecture yesterday morning in which they...
Special VAM session underscores ‘complementary’ nature of open and endovascular strategies in CLTI patients
A dedicated session at VAM 2023 saw speakers and delegates gather to debate, analyse and consider the implementation of the BEST-CLI and BASIL-2 randomized-controlled...
The global burden of CLTI: ESVS President points toward need for new global vascular...
Early-bird VAM 2023 attendees yesterday gained broad insight into the issues facing vascular surgeons around the world, with the tone set from the opening...
Analyses offer a deeper dive into BEST-CLI trial data
As the vascular community continues to digest key insights from the BEST-CLI randomized controlled trial (RCT), attendees of Plenary Session 3 at the Vascular...
Base revascularization strategy on effectiveness in restoring adequate and durable limb perfusion, BEST-CLI subanalysis...
The results of a subanalysis of the BEST-CLI trial found that patients with chronic limb-threatening ischemia (CLTI) who were deemed suitable for open lower-extremity...
BASIL-2 and BEST-CLI: A tale of two limb trials
Optimal treatment of patients with chronic limb-threatening ischemia (CLTI) has been an ongoing debate within the vascular community, fueled by growing numbers of patients,...
SVS webinar discusses BEST-CLI and early impacts on practice
A recording of the inaugural “SVS Presents” virtual educational session, on the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb...
The top 10 most popular Vascular Specialist stories of April 2023
In April 2023, Vascular Specialist readers were drawn to an interview dissecting the role robotics play, and can play in the future, in vascular...
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients
A question from Manj Gohel, MD, from Cambridge University Hospitals in Cambridge, England, on what the 2023 Charing Cross (CX) International Symposium audience should...
The top 10 most popular Vascular Specialist stories of March 2023
In March 2023, the Vascular Specialist stories grabbing readers' attention were a response to a February letter addressing vascular surgeons' use of social media; an...
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’ of deep vein...
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia...
SCVS 2023: Endovascular-first or -only approach to all CLTI patients ‘is not evidence-based care’
Michael S. Conte, MD, one of the foremost experts in the field of peripheral arterial disease (PAD), took attendees of the 2023 annual meeting...
Florida hospital targets lingering disparities in limb salvage with region’s first multidisciplinary Limb Preservation...
This advertorial is sponsored by Tampa General Hospital.
Operating in Tampa, Florida, Charles J. Bailey, MD, and his partners in the Division of Vascular Surgery...
VESS 2023: pMAC score found to be ‘important predictor’ of CLTI revascularization outcomes
Having observed a strong relationship between calcification and subsequent limb loss, a research team led by investigators from the University of California San Francisco...
BioGenCell begins recruitment for clinical trial of stem cell-based treatment for preventing limb amputation
BioGenCell has announced that it is recruiting for an international clinical trial to assess the company's stem cell-based therapy for chronic limb-threatening ischemia patients...
SVS Foundation changes name of program aimed at providing care for underserved patients
The Society for Vascular Surgery (SVS) Foundation program formerly known as VISTA has a new name. VISTA—an acronym for Vascular Volunteers In Service To...
Vascular community starts process of wrestling with findings from BEST-CLI
One of the earliest multispecialty public gatherings of the vascular community following the release of the first results from the BEST-CLI randomized controlled...
VSGBI spotlights data-driven financial incentives for PAD revascularization
The President’s Symposium at the Vascular Society of Great Britain and Ireland (VSGBI) annual scientific meeting (Nov. 23–25) in Brighton, England, saw Rob Sayers,...
Paclitaxel DCB performs well in ‘challenging anatomy’ of femoropopliteal in-stent restenosis, VQI registry data...
The IN.PACT Admiral drug-coated balloon (DCB) shows promising results in treating femoropopliteal in-stent restenosis (ISR) in a Society for Vascular Surgery (SVS) Vascular Quality...
The 10 most popular Vascular Specialist stories of November 2022
Among November's most read Vascular Specialist stories were updates from the BEST-CLI trial in the form of new data and funding; a guest...
Miss the SVS webinars? Take advantage of the recordings
The Society for Vascular Surgery (SVS) hosts a number of Town Halls, roundtables and webinars for the benefit of its members.
In the past few...
SWING trial 12-month data: Novel sirolimus DCB shows ‘great promise’ in ‘challenging’ CLTI population
The Sundance (Surmodics) sirolimus drug-coated balloon (DCB) has an “excellent” safety profile in a “challenging, real-world, predominantly CLTI population,” and has a primary...
First data from BEST-CLI bring surgical bypass into the forefront of discussion for patients...
The first results from the BEST-CLI randomized controlled trial (RCT) of 1,830 patients show that surgical bypass with adequate single-segment great saphenous vein (GSV)...
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66% at six months
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint...
‘Excellent’ three-year results presented for the BioMimics 3D stent in longer lesions
At the 2022 Vascular Interventional Advances (VIVA) meeting (Oct. 31–3 Nov. 3), Michael Lichtenberg, MD, from Arnsberg Clinic, Arnsberg, Germany, reported a subgroup analysis...
Six-month data from SWING below-the-knee, first-in-human trial presented at AMP Europe
Six-month data from the Surmodics SWING first-in-human (FIH) study of the company’s Sundance sirolimus drug-coated balloon (DCB) were shared at the 2022 Amputation Prevention Symposium (AMP) held Oct....
Roundtable for treating CLTI: GLASS will make it clear
The final of three roundtables on treating Chronic Limb-threatening Ischemia (CLTI) will cover the Global Limb Anatomic Staging System—GLASS.
The virtual roundtable, on GLASS staging...
VEITHsymposium to include world federation session
The World Federation of Vascular Societies (WFVS) is set to hold a session in November during the VEITHsymposium in New York City. The 90-minute session...
Treating PAD: ‘Run, don’t walk, to sign up for this incredible course’
No matter if you’re a surgeon with a few years—or a few decades—of experience, faculty members of a new, upcoming Society for Vascular Surgery...
CLTI: Translating guidelines into practice
Clinical practice guidelines (CPG) are integral to helping achieve optimal patient care. The Society for Vascular Surgery (SVS) clinical guidelines are evidence-based and the...
Digging deep into DOACs for PAD post-revascularization in fight to stave off amputation
This advertorial is sponsored by ACHL.
“It’s really sad—but it’s true: In the PAD space, we’re really behind. We’re behind in our understanding of the...
The top 10 most popular Vascular Specialist items of June 2022
June's top stories spanned a range of presentations from the 2022 Vascular Annual Meeting (VAM) in Boston (June 15–18), covering topics including burnout...
First results from BEST-CLI poised to reveal ‘very low’ quality of life for patients...
An analysis from the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial presented at the 2022 Vascular Annual...
Researchers report higher three-year amputation and reintervention rates in Black and Hispanic CLTI patients
In a study of over 7,000 chronic limb-threatening ischemia (CLTI) patients, researchers found that Black and Hispanic patients had higher three-year amputation and reintervention...
SVS special membership sections stage education sessions
For the first time, all those who are part of the five Society for Vascular Surgery (SVS) membership sections have educational presentations geared specifically...
Open surgical bypass to distal targets at the ankle is ‘viable’ infrapopliteal CLTI treatment
The Vascular and Endovascular Surgical Society (VESS) Paper Session at the Vascular Annual Meeting (VAM) in Boston on Wednesday, June 15, will see Othman...
Revascularization strategy for BTK intervention should hinge on diagnostic modality, LINC hears
New data provide “another argument” for the use of intravascular ultrasound (IVUS) in below-the-knee (BTK) interventions. This is according to Michael Lichtenberg, MD, from Arnsberg...
Register today for two SVS courses
Registration has opened—along with early-bird pricing—for two Society for Vascular Surgery (SVS) in-person courses in coding and reimbursement, and peripheral artery disease (PAD) skills....
New long-term data of paclitaxel devices continue to show no increased mortality compared to...
New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented today as late-breaking clinical research at...
Tissue samples show paclitaxel effect in minority of CLTI patients receiving DCB angioplasty, study...
Paclitaxel effect was witnessed in tissue specimens of a minority of chronic limb-threatening ischemia (CLTI) patients treated with drug-coated balloons (DCBs)—but was not dependent...
Non-optimal therapy for CLTI ‘more prominent in females’
A real-world claims data analysis of nearly 200,000 patients with chronic limb-threatening ischemia (CLTI) showed that female patients were older, underwent vascular procedures less often, and...
The top 10 most popular Vascular Specialist stories in April 2022
The digital version of the April 2022 issue of Vascular Specialist, the most recent editorial by our medical editor focusing on diversity within the...
SCAI releases multi-society position statement focused on core competencies for endovascular specialists providing care...
The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement outlining competencies for endovascular specialists who provide care for chronic limb-threatening...
CLTI, VTE and post-thrombotic syndrome: Leading experts discuss crucial decision-making in interventional approaches
This advertorial is sponsored by ACHL.
For Anahita Dua, MBChB, the stark realities and complexities of peripheral arterial disease (PAD) patients undergoing endovascular treatment for...
SCVS 2022: WIfI score does not predict successful healing after transmetatarsal amputation, study finds
A higher initial Wound, ischemia, and foot infection (WIfI) classification score at initial presentation in chronic limb-threatening ischemia (CLTI) patients who underwent a transmetatarsal...
Boston calling: Registration for VAM 2022 is open
Registration and housing for the Society for Vascular Surgery (SVS) 2022 Vascular Annual Meeting (VAM) are now open. This year’s premiere educational event for...
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI patients completes enrollment
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called "no-option"...
Strength in numbers: Global VASCC COVID-19 project helps identify framework to tackle delayed cases
When Robert Cuff, MD, and Max Wohlauer, MD, first launched the Vascular Surgery COVID-19 Collaborative (VASCC) back in the spring of 2020, the pandemic...
Cook Medical receives FDA breakthrough designation for new drug-eluting stent
Cook Medical has received Breakthrough Device designation from the Food and Drug Administration (FDA) on a new drug-eluting stent (DES) for below the knee...
ISET 2022 audience hears latest data on endovascular therapies
At this year’s International Symposium on Endovascular Therapy (ISET), being held Jan. 16–19 in Hollywood, Florida, experts presented an array of late-breaking trial results...
Learn by doing at February SVS PAD workshop
The Society for Vascular Surgery (SVS) Peripheral Arterial Disease (PAD) Workshop in February will feature four hours of hands-on surgical skills training, on 10...
First patient enrolled in Disrupt BTK II study for long, calcified, below-the-knee lesions
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the Shockwave...
Philips announces large-scale study outcomes on use of IVUS in peripheral interventions
Royal Philips has announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services (CMS) data on the health...
WIfI system helps predict revascularization benefit for diabetic patients with CLTI, study finds
A retrospective study supports the use of the Wound, ischemia, and foot infection (WIfI) classification system to predict the revascularization benefit for diabetic patients with chronic limb-threatening ischemia...
‘Proceed cautiously in use of DCBs in CLTI patients with advanced WIfI stage’
The last several years have seen ongoing controversy and debate about the risks and benefits of paclitaxel-coated devices (PCDs) for patients with peripheral arterial...
PCBs: Panel of vascular surgeons review latest findings on paclitaxel-coated balloons
A recent meta-analysis by Konstantinos Katsanos, MD, of Patras University Hospital, Rion, Greece, and colleagues—“Risk of major amputation following application of paclitaxel-coated balloons ...
Amputation rates higher for people with PAD who are poor or Black
Poverty and Black race were associated with higher rates of lower-leg amputation among people with peripheral arterial disease (PAD) who live in metropolitan areas, according to new...
Vascular Quality Initiative launches ‘My PAD’ pilot
The Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) has created “My PAD,” a pilot program for collecting patient-reported outcomes (PROs) from patients...
Veterans with claudication who undergo revascularization ‘significantly more likely to have major amputation than...
Patients within the Veterans Affairs Administration healthcare system who underwent an intervention for intermittent claudication (IC) were consistently at three-to-four times greater risk of...
Annual Business Meeting—for members only
Attend Saturday’s Society for Vascular Surgery (SVS) Annual Business Meeting to participate in important Society business. This is SVS’ second Annual Business Meeting for...
PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrollment
MedAlliance has announced completion of patient enrollment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of patients with below-the-knee...
The year in COVID: VAM to feature 10 talks probing pandemic-related vascular complications
After nearly 18 months of life dominated by a worldwide pandemic—one that canceled the 2020 Vascular Annual Meeting (VAM)—VAM 2021 highlights several aspects of...
Introducing patient-reported outcomes into the VQI
Vascular specialists have long recognized that there is more to the treatment of peripheral arterial disease (PAD) than the immediate procedural success and early...
The top 10 most popular Vascular Specialist stories in May
A pointed letter aimed at electronic health record (EHR) behemoth Epic, an argument in favor of endovascular treatment of ruptured abdominal aortic aneurysms (rAAAs)...
Philips announces positive two-year data from TOBA II BTK clinical trial
Royal Philips recently announced positive two-year results from the TOBA (Tack optimized balloon angioplasty) II below-the-knee (BTK) clinical trial.
The data show the Philips Tack endovascular...
One-year results from PROMISE I study of LimFlow system in ‘no-option’ CLTI patients published
Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been...
Innovation: ISET audience hears what’s on the horizon for CLTI patients
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider, MD, professor of vascular and endovascular surgery...
MicroStent to treat PAD below the knee receives FDA breakthrough device designation
Micro Medical Solutions (MMS) recently revealed Food and Drug Administration (FDA) breakthrough device designation for its MicroStent vascular stent. This novel technology is designed...
Lessons in PAD care from VA vascular surgeons
The care of patients with peripheral arterial disease (PAD) is challenging and costly. Every practicing vascular surgeon knows that when patients present with ulcerations,...
‘A reliable tool’: Positive findings for 2D perfusion angiography in CLTI patients
Researchers suggest that in patients with chronic limb-threatening ischemia (CLTI), two-dimensional (2D) perfusion angiography is a “reliable tool” when used according to standardized methods. Jetty...
Study identifies ‘critical need’ for guidelines on appropriate use of atherectomy
No data currently exist to support the use of atherectomy over other procedures for the treatment of peripheral arterial disease (PAD), and the healthcare...
Surgeons discuss early efforts rolling out SVS Branding Toolkit
Two-and-a-half years back, when Kathryn E. Bowser, MD, joined her current institution as a vascular surgeon, a confluence of unfolding events led her to...
Data show potential of Limflow system to improve outcomes for no-option CLTI
“Deep vein arterialization is safe and technically feasible,” Peter Schneider, MD, a professor in the division vascular and endovascular surgery at the University of...
Patients with depression ‘less likely’ to go home after CLTI revascularization
A recent analysis established an association between depression and non-home discharge after revascularization for chronic limb-threatening ischemia (CLTI)—providing further evidence, the authors say, that...
Target 2021: SVS councils and committees drill down on key goals for year ahead...
While there is little doubt the pandemic has impacted each vascular surgeon and the SVS as a Society in numerous ways, the commitment and...
Quality initiative: New pocket guides now available
New pocket guides of the Society for Vascular Surgery (SVS) clinical practice guidelines and reporting standards are now available, with printed guides sent to...
WIfI score found to be accurate across racial groups
The wound, ischemia and foot infection (WIfI) score is as accurate a predictor of risk for limb loss in Black people as it is...
SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for paclitaxel devices
An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease (PAD) received treatment with paclitaxel-coated (drug-coated balloons...
The benefits of an academic research career in the VA
Every year a number of graduating vascular trainees look for jobs in academic surgery to develop a career as a surgeon-scientist in basic, translational...
SVS pushes out trio of mobile apps to aid CLTI treatment
The Society for Vascular Surgery (SVS) has launched three new mobile apps to help guide surgeons in the treatment and management of chronic limb-threatening...
Foot vein arterialization study shows 77.8% limb salvage rate
Foot vein arterialization (FVA) is a safe procedure with good early graft patency and a limb salvage rate of 77.8%, Qi Yan, MD, and...
Diabetes Awareness Month: The utility of SVS branding fliers for diabetic foot ulcers
November is Diabetes Awareness Month. The Branding Toolkit can help SVS members promote the valuable care they provide those with the disease.
One of...
Previously described patient-centered clinical success measure after revascularization for diabetic foot wounds may be...
Patient-centered clinical success after lower-extremity revascularization for people with diabetic foot wounds was achieved among 63% of patients in a new analysis—but researchers suggest...
Anatomy of a branding campaign: Making vascular surgery more visible
Members asked; SVS listened. The Society for Vascular Surgery (SVS) has launched a Branding Toolkit to help its members brand the specialty in order...
Utilize new SVS Branding Toolkit
The new SVS Branding Toolkit—a robust set of tools designed to help members communicate their roles in comprehensive vascular care—is now available exclusively and...
VA system delivers high quality services for veterans
Vascular surgery in the Veterans Health Administration has always been a robust service, developing into a mature specialty around the time of the Vietnam...
Medicare reimbursement fails to adequately cover cost of care after open bypass surgery among...
For most patients with chronic limb-threatening ischemia (CLTI), Medicare reimbursement for lower extremity bypass surgery does not adequately account for case complexity in the...
‘Rapid reduction’ in amputations follows opening of multidisciplinary limb preservation service
A multidisciplinary limb preservation service under the leadership of vascular surgery in a level one trauma center was associated with an immediate and rapid...
SPECIAL REPORT: Reacting to virus in key locations across United States
Following on from part one of our June issue special report in which we explored global perspectives on how vascular surgeons were coping with...
CX 2020 LIVE pioneers virtual vascular conference format in COVID-19 era
CX 2020 LIVE came to life online—despite COVID-19—using state-of-the art broadcast technology to bring together more than 1,000 vascular specialists, live, from 95 countries across...
Positive two-year data from ALPS registry of LimFlow system published
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialization (pDVA) system. Results were published...
Registry launches pair of studies on vascular complications related to COVID-19
The new Vascular Surgery COVID-19 Collaborative (VASCC) is ready to start collecting data on two projects.
The first study to emerge from the international registry,...
Deploying robust, detailed SVS VQI data to help better define role of paclitaxel technology...
In December 2018, the Journal of the American Heart Association published “Risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal...
New meta-analysis finds ‘no observed difference’ in mortality between paclitaxel and uncoated device use...
February 2020 brings another paclitaxel device meta-analysis of randomized controlled trials in chronic limb-threatening ischemia (CLTI) patients. Krystal Dinh, BMed, of Westmead Hospital, Sydney,...
Global vascular guidelines for CLTI are gaining traction but work remains to raise awareness...
The application of new global vascular guidelines for chronic limb-threatening ischemia (CLTI) provides an opportune and worthwhile window to revisit the concept of critical...
When world vascular societies combined to produce new global guidelines for CLTI
Four years ago, vascular experts from around the world were tasked with a quest to get all surgeons and providers to agree on the...
New CLTI Global Guidelines Available
On May 31, new global guidelines on the best ways to treat Chronic Limb-Threatening Ischemia were co-published in the Journal of Vascular Surgery and...
Malnutrition Exacerbated Outcomes in Frail Elderly Patients Treated for PAD
Frailty increasingly has been seen as a factor in procedural outcomes, including vascular surgery. Nutrition factors among older adults have also become an issue...
RAS Inhibitors Show Promise for CLTI Patients After Interventions
Physicians should consider prescribing high-dose angiotensin inhibitors for patients with chronic limb-threatening ischemia (CLTI), a recent study from Harvard University suggests.
The report was published...
What the cost of cancer care teaches vascular specialists
How does the cost of treating critical limb-threatening ischemia (CLTI) in the U.S. stack up to cancer care? That was the question at the...
The role of deep venous arterialization comes under scrutiny
"Every so often in vascular disease, disruptive technologies come along and the question really is, ‘Is this going to make a big impact on...
Viabahn use in claudicants with long, complex SFA lesions ‘safe and effective’ through five...
Recently published research indicates that stent grafting with the Viabahn endoprosthesis (W L Gore & Associates) of long and complex superficial femoral artery (SFA) lesions in...
New analysis finds DCBs lead to greater four-year survival after fempop revascularization
Patients treated with a paclitaxel-coated balloon saw greater survival, freedom from amputation and amputation-free survival through four-year follow-up after their initial femoropopliteal revascularization operation...
First US commercial use of Tack Endovascular System in BTK arteries announced
Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the United States.
Notably the first Food...
Study: Link between IC revascularization and progression to CLTI established alongside rising rate of...
PALM BEACH, Fla.—Revascularization of intermittent claudication (IC) patients is associated with an increased rate of progression to critical limb-threatening ischemia (CLTI)—as well as an...
Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization
Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of...
Letter from Seattle: Amid COVID-19 pandemic, time to act is long past due
SEATTLE—We live in unprecedented times. On Jan. 19, patient zero arrived in the United States at Seattle-Tacoma International Airport after returning from a visit...
